M J KNAPP
Overview
Explore the profile of M J KNAPP including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
KNAPP M, Seebeck F, Klinman J
J Am Chem Soc
. 2001 Jul;
123(12):2931-2.
PMID: 11457000
No abstract available.
2.
KNAPP M, Krzystek J, Brunel L, Hendrickson D
Inorg Chem
. 2001 Mar;
39(2):281-8.
PMID: 11272536
High-frequency (94-371 GHz) EPR data are reported for powdered samples of [PPh4]2[Fe(SPh)4], an accurate model for the reduced site of rubredoxins. This is the first HFEPR investigation of an S...
3.
Fontana R, deVries T, Woolf T, KNAPP M, Brown A, Kaminsky L, et al.
Br J Clin Pharmacol
. 1998 Oct;
46(3):221-8.
PMID: 9764962
Aims: To study the potential utility of caffeine based probes of CYP1A2 enzyme activity in predicting the pharmokinetics of tacrine in patients with Alzheimer's disease. Methods: The pharmokinetics of a...
4.
Gracon S, KNAPP M, Berghoff W, Pierce M, DeJONG R, Lobbestael S, et al.
Alzheimer Dis Assoc Disord
. 1998 Jul;
12(2):93-101.
PMID: 9651138
The safety of tacrine (Cognex), a centrally active, reversible acetylcholinesterase inhibitor approved in 1993 for the treatment of mild to moderate dementia of the Alzheimer type, was evaluated in 2,706...
5.
Solomon P, KNAPP M, Gracon S, Groccia M, Pendlebury W
Lancet
. 1996 Jul;
348(9022):275-6.
PMID: 8684234
No abstract available.
6.
Fontana R, Turgeon D, Woolf T, KNAPP M, Foster N, Watkins P
Hepatology
. 1996 Jun;
23(6):1429-35.
PMID: 8675160
Therapy with tacrine, a promising new treatment for Alzheimer's disease, must be discontinued in up to 15% of patients because of hepatocellular toxicity. Recent studies using human liver microsomes have...
7.
Green V, Pirmohamed M, Kitteringham N, KNAPP M, Park B
Br J Clin Pharmacol
. 1995 Apr;
39(4):411-5.
PMID: 7640148
1. Tacrine (1,2,3,4-tetrahydro-9-aminoacridine) which is used in Alzheimer's disease, causes elevation of liver transaminases ('tacrine transaminitis') in 40-50% of patients. This may be related to the formation of a chemically...
8.
Knopman D, KNAPP M, Gracon S, Davis C
Neurology
. 1994 Dec;
44(12):2315-21.
PMID: 7991118
Global assessments are Food and Drug Administration-required primary outcome measures in trials of putative antidementia drugs. Global ratings are intended to provide an index of clinical importance of change that...
9.
Crapo J, Hayatdavoudi G, KNAPP M, Fracica P, Wolfe W, Piantadosi C
Am J Physiol
. 1994 Dec;
267(6 Pt 1):L797-806.
PMID: 7810684
Moderate exposures to hyperoxia are becoming increasingly common in clinical medicine as advancing technology allows O2 to be more effectively delivered to nonintubated patients. The sensitivity of the lung to...
10.
Watkins P, ZIMMERMAN H, KNAPP M, Gracon S, Lewis K
JAMA
. 1994 Apr;
271(13):992-8.
PMID: 8139084
Objective: To characterize the hepatic effects of tacrine treatment in patients with Alzheimer's disease. Design: Controlled trials of tacrine therapy consisting of two blinded, parallel-group trials; three blinded, enrichment-design trials;...